These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17636693)

  • 1. Photodynamic therapy for neovascular age-related macular degeneration.
    Wormald R; Evans J; Smeeth L; Henshaw K
    Cochrane Database Syst Rev; 2007 Jul; (3):CD002030. PubMed ID: 17636693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photodynamic therapy for neovascular age-related macular degeneration.
    Wormald R; Evans J; Smeeth L; Henshaw K
    Cochrane Database Syst Rev; 2005 Oct; (4):CD002030. PubMed ID: 16235294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Photodynamic therapy for neovascular age-related macular degeneration.
    Wormald R; Evans J; Smeeth L; Henshaw K
    Cochrane Database Syst Rev; 2003; (2):CD002030. PubMed ID: 12804420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photodynamic therapy for neovascular age-related macular degeneration.
    Wormald R; Evans J; Smeeth L; Henshaw K
    Cochrane Database Syst Rev; 2001; (3):CD002030. PubMed ID: 11687007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photodynamic therapy for neovascular age-related macular degeneration.
    Wormald R; Evans J; Smeeth L
    Cochrane Database Syst Rev; 2000; (2):CD002030. PubMed ID: 10796845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2014 Aug; 8(8):CD005139. PubMed ID: 25170575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Verteporfin photodynamic therapy for neovascular age-related macular degeneration: cohort study for the UK.
    Reeves BC; Harding SP; Langham J; Grieve R; Tomlin K; Walker J; Guerriero C; Carpenter J; Patton WP; Muldrew KA; Peto T; Chakravarthy U
    Health Technol Assess; 2012; 16(6):i-xii, 1-200. PubMed ID: 22348600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4.
    Azab M; Benchaboune M; Blinder KJ; Bressler NM; Bressler SB; Gragoudas ES; Fish GE; Hao Y; Haynes L; Lim JI; Menchini U; Miller JW; Mones J; Potter MJ; Reaves A; Rosenfeld PJ; Strong A; Su XY; Slakter JS; Schmidt-Erfurth U; Sorenson JA; ;
    Retina; 2004 Feb; 24(1):1-12. PubMed ID: 15076937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
    Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration.
    Vedula SS; Krzystolik MG
    Cochrane Database Syst Rev; 2008 Apr; (2):CD005139. PubMed ID: 18425911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.
    Blinder KJ; Bradley S; Bressler NM; Bressler SB; Donati G; Hao Y; Ma C; Menchini U; Miller J; Potter MJ; Pournaras C; Reaves A; Rosenfeld PJ; Strong HA; Stur M; Su XY; Virgili G; ;
    Am J Ophthalmol; 2003 Sep; 136(3):407-18. PubMed ID: 12967792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photodynamic therapy in practice: a review of the results of the first 12 months experience with verteporfin at the Royal Victorian Eye and Ear Hospital.
    Essex RW; Qureshi SH; Cain MS; Harper CA; Guymer RH
    Clin Exp Ophthalmol; 2003 Dec; 31(6):476-81. PubMed ID: 14641153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.
    Verteporfin In Photodynamic Therapy Study Group
    Am J Ophthalmol; 2001 May; 131(5):541-60. PubMed ID: 11336929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.
    Schmidt-Erfurth U; Miller JW; Sickenberg M; Laqua H; Barbazetto I; Gragoudas ES; Zografos L; Piguet B; Pournaras CJ; Donati G; Lane AM; Birngruber R; van den Berg H; Strong HA; Manjuris U; Gray T; Fsadni M; Bressler NM
    Arch Ophthalmol; 1999 Sep; 117(9):1177-87. PubMed ID: 10496389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Full macular translocation versus photodynamic therapy with verteporfin in the treatment of neovascular age-related macular degeneration: 1-year results of a prospective, controlled, randomised pilot trial (FMT-PDT).
    Gelisken F; Voelker M; Schwabe R; Besch D; Aisenbrey S; Szurman P; Grisanti S; Herzau V; Bartz-Schmidt KU
    Graefes Arch Clin Exp Ophthalmol; 2007 Aug; 245(8):1085-95. PubMed ID: 17219106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Full macular translocation (FMT) versus photodynamic therapy (PDT) with verteporfin in the treatment of neovascular age-related macular degeneration: 2-year results of a prospective, controlled, randomised pilot trial (FMT-PDT).
    Lüke M; Ziemssen F; Völker M; Altpeter E; Beutel J; Besch D; Bartz-Schmidt KU; Gelisken F
    Graefes Arch Clin Exp Ophthalmol; 2009 Jun; 247(6):745-54. PubMed ID: 19214552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.
    Bressler NM; Arnold J; Benchaboune M; Blumenkranz MS; Fish GE; Gragoudas ES; Lewis H; Schmidt-Erfurth U; Slakter JS; Bressler SB; Manos K; Hao Y; Hayes L; Koester J; Reaves A; Strong HA;
    Arch Ophthalmol; 2002 Nov; 120(11):1443-54. PubMed ID: 12427056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Verteporfin : a review of its use in the management of subfoveal choroidal neovascularisation.
    Keam SJ; Scott LJ; Curran MP
    Drugs; 2003; 63(22):2521-54. PubMed ID: 14609361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
    Kaiser PK; ; Boyer DS; Garcia R; Hao Y; Hughes MS; Jabbour NM; Kaiser PK; Mieler W; Slakter JS; Samuel M; Tolentino MJ; Roth D; Sheidow T; Strong HA
    Ophthalmology; 2009 Apr; 116(4):747-55, 755.e1. PubMed ID: 19243834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study.
    Kaiser PK; Boyer DS; Cruess AF; Slakter JS; Pilz S; Weisberger A;
    Ophthalmology; 2012 May; 119(5):1001-10. PubMed ID: 22444829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.